NCT00162851已完成2 期
A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia
Karolinska University Hospital2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2003年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 2
研究概览
简要总结
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •B-CLL that has failed fludarabine
排除标准
- •Performance status grade 3
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaL1 Adult Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaL2 Adult Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic LeukemiaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic LeukemiaAcute Undifferentiated LeukemiaNCT00061945National Cancer Institute (NCI)302
终止
1 期
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe PsoriasisPsoriasisNCT00954915MacroGenics1
进行中（未招募）
2 期
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)Squamous Cell CarcinomaNCT06041802Merck Sharp & Dohme LLC19
已完成
2 期
A Study of ELX-02 in Patients With Alport SyndromeAlport SyndromeNCT05448755Eloxx Pharmaceuticals, Inc.3
进行中（未招募）
1 期
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLB Cell Precursor Acute Lymphoblastic LeukemiaNCT04521231Amgen181